Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial.

Lofwall MR, Nunes EV, Walsh SL, Bailey GL, Frost M, Budilovsky-Kelley NR, Banke Nordbeck E, Meyner S, Almgren P, Peterson S, Tiberg F

Open source

DOI: 10.1097/adm.0000000000001484
Published: 2025 Nov-Dec 01
Container: Journal of addiction medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/adm.0000000000001484,
  title = {Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial.},
  author = {Lofwall MR and Nunes EV and Walsh SL and Bailey GL and Frost M and Budilovsky-Kelley NR and Banke Nordbeck E and Meyner S and Almgren P and Peterson S and Tiberg F},
  year = {2025},
  journal = {Journal of addiction medicine},
  doi = {10.1097/adm.0000000000001484},
  url = {https://doi.org/10.1097/adm.0000000000001484}
}

RIS

TY  - JOUR
TI  - Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial.
AU  - Lofwall MR
AU  - Nunes EV
AU  - Walsh SL
AU  - Bailey GL
AU  - Frost M
AU  - Budilovsky-Kelley NR
AU  - Banke Nordbeck E
AU  - Meyner S
AU  - Almgren P
AU  - Peterson S
AU  - Tiberg F
PY  - 2025
JO  - Journal of addiction medicine
DO  - 10.1097/adm.0000000000001484
UR  - https://doi.org/10.1097/adm.0000000000001484
ER  -

APA

MR, L., EV, N., SL, W., GL, B., M, F., NR, B., E, B. N., S, M., P, A., S, P., & F, T. (2025). Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial.. Journal of addiction medicine. https://doi.org/10.1097/adm.0000000000001484

Source records

pubmed · retrieved 2026-09-26T20:08:15.500Z